Mark Alan Goldberg, SVP, Product Development at SYNAGEVA BIOPHARMA CORP (GEVA), sold 4,417 shares at $48.02 ($211K) on 2013-02-01, disclosed to the SEC on 2013-02-05.
Scheduled sale ($211k) by SVP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.33 | 1,757 | $83K | 39.4% |
| 2 | $48.02 | 2,660 | $128K | 60.6% |
| Total | $47.75 avg | 4,417 | $211K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |